PHI to BioStock: “We aim to revolutionize the regenerative medicine market “

A year ago, Patrik Eschricht assumed the role of CEO at PHI, heralding the shift towards regenerative medicine and a commitment to enhancing shareholder value. This transition was further underscored by the entry of private Swiss distributor and investment company Altium as a major shareholder. BioStock talked to Patrik Eschricht to reflect on the past year and explore his vision for the company’s future.

Read the full interview with Patrik Eschricht at biostock.se:

https://www.biostock.se/en/2024/02/phi-we-aim-to-revolutionize-the-regenerative-medicine-market/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/